Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Virchows Archiv

Volumn 469, Issue 5, 2016, Pages 489-503

  Bubendorf, Lukas ^a   Büttner, Reinhard ^b   Al Dayel, Fouad ^c   Dietel, Manfred ^d   Elmberger, Göran ^e   Kerr, Keith ^f   López Ríos, Fernando ^g   Marchetti, Antonio ^h   Öz, Büge ⁱ   Pauwels, Patrick ^j   Penault Llorca, Frédérique ^k   Rossi, Giulio ^l   Ryška, Aleš ^m   Thunnissen, Erik ⁿ  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g Hospital Universitario HM Sanchinarro   (Spain)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k CENTRE JEAN PERRIN   (France)

^l Aosta Hospital   (Italy)

^m UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

ⁿ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Fluorescence in situ hybridisation; Immunohistochemistry; Non small cell lung cancer; Predictive marker; ROS1; RT PCR

Indexed keywords

BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN ROS1; UNCLASSIFIED DRUG; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM; ONCOGENE;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84982273316     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-016-2000-3     Document Type: Review

References (87)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262
2. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Spanish Lung Cancer Group in collaboration with Groupe Francais de P-C, Associazione Italiana Oncologia T Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. doi:10.1016/S1470-2045(11)70393-X
3. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, Investigators P (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177. doi:10.1056/NEJMoa1408440
4. Savas P, Hughes B, Solomon B (2013) Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 5(Suppl 5):S579–S592. doi:10.3978/j.issn.2072-1439.2013.08.52
5. Shaw AT, Forcione DG, Digumarthy SR, Iafrate AJ (2011) Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med 365(2):158–167. doi:10.1056/NEJMcpc1102202
6. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su P-F (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama 311(19):1998–2006
7. Network TCGAR (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (7511):543-550. doi: 10.1038/nature13385 http://www.nature.com/nature/journal/v511/n7511/abs/nature13385.html#supplementary-information
8. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963–1971. doi:10.1056/NEJMoa1406766
9. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870. doi:10.1200/JCO.2011.35.6345
10. Pfizer. (2016) Crizotinib Summary of Product Characteristics.
11. Pfizer. (2016) Crizotinib Prescribing Information.
12. FDA (2016) FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm490329.htm.
13. Shibuya M, Hanafusa H, Balduzzi PC (1982) Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells. J Virol 42(1):143–152
14. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D (2003) Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del (6) (q21q21). Genes Chromosom Cancer 37(1):58–71. doi:10.1002/gcc.10207
15. Acquaviva J, Wong R, Charest A (2009) The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 1795(1):37–52. doi:10.1016/j.bbcan.2008.07.006
16. Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19(15):4040–4045. doi:10.1158/1078-0432.CCR-12-2851
17. Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC (2014) Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer 83(3):389–395. doi:10.1016/j.lungcan.2014.01.003
18. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150(6):1121–1134. doi:10.1016/j.cell.2012.08.024
19. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190–1203. doi:10.1016/j.cell.2007.11.025
20. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18(16):4449–4457. doi:10.1158/1078-0432.CCR-11-3351
21. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22(11):2109–2119. doi:10.1101/gr.145144.112
22. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18(3):378–381. doi:10.1038/nm.2658
23. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H (2013) ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 37(4):554–562. doi:10.1097/PAS.0b013e3182758fe6
24. Birchmeier C, Sharma S, Wigler M (1987) Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 84(24):9270–9274
25. Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A (2012) The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 72(15):3764–3774. doi:10.1158/0008-5472.CAN-11-3990
26. Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, Housman D (2003) Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A 100(3):916–921. doi:10.1073/pnas.242741799
27. Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Lena H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouviere D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33(9):992–999. doi:10.1200/JCO.2014.58.3302
28. Moro-Sibilot D, Faivre L, Zalcman G, Perol M, Mazières J, Barlesi F, Otto J, Monnet I, Cortot A, Wislez M, Léna H, Souquet PJ, Lantuejoul S, Rouquette I, Mcleer-Florin A, Ferretti G, Hoog-Labouret N, Nowak F, Jimenez M, Vassal G (2015) Crizotinib in patients with ROS1 NSCLC. Preliminary results of the AcSé trial. J Thorac Oncol 10(9):S261–S406. doi:10.1016/S1556-0864(16)30011-9
29. Goto K, Yang JCH, Kim D-W, Lu S, Seto T, Yang J-J, Yamamoto N, Ahn M-J, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Wilner K, Wu Y-L (2016) Phase II study of crizotinib in East Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 34(15 suppl.):Abstr. 9022
30. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394. doi:10.1056/NEJMoa1214886
31. Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, Garcia RC, Kerr KM, Lim E, Lopez-Rios F, Thunnissen E, Van Schil PE, von Laffert M (2016) Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 71(2):177–184. doi:10.1136/thoraxjnl-2014-206677
32. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461(3):245–257. doi:10.1007/s00428-012-1281-4
33. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E, Panel M, Panel M (2014) Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25(9):1681–1690. doi:10.1093/annonc/mdu145
34. Thunnissen E, van der Oord K, den Bakker M (2014) Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 464(3):347–358. doi:10.1007/s00428-014-1535-4
35. Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18(7):865–875. doi:10.1634/theoncologist.2013-0095
36. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A (2014) On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 83(2):168–173. doi:10.1016/j.lungcan.2013.11.019
37. Shan L, Lian F, Guo L, Qiu T, Ling Y, Ying J, Lin D (2015) Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One 10(3):e0120422. doi:10.1371/journal.pone.0120422
38. Jin Y, Sun PL, Kim H, Park E, Shim HS, Jheon S, Kim K, Lee CT, Chung JH (2015) Erratum to: ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch 467(1):123. doi:10.1007/s00428-015-1775-y
39. Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, Ardizzoni A (2015) ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagn Cytopathol 43(11):941–946. doi:10.1002/dc.23318
40. Savic S, Bubendorf L (2012) Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 56(6):611–621. doi:10.1159/000339792
41. Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR (2015) ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer 16(2):106–111. doi:10.1016/j.cllc.2014.10.003
42. Cao B, Wei P, Liu Z, Bi R, Lu Y, Zhang L, Zhang J, Yang Y, Shen C, Du X, Zhou X (2016) Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther 9:131–138. doi:10.2147/OTT.S94997
43. Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Janne PA, Rodig SJ (2013) ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 37(9):1441–1449. doi:10.1097/PAS.0b013e3182960fa7
44. Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, Shibata T, Furuta K, Kohno T, Kushima R (2014) Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 27(5):711–720. doi:10.1038/modpathol.2013.192
45. Rogers TM, Russell PA, Wright G, Wainer Z, Pang JM, Henricksen LA, Singh S, Stanislaw S, Grille J, Roberts E, Solomon B, Fox SB (2015) Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol 10(4):611–618. doi:10.1097/JTO.0000000000000465
46. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24(2):69–78. doi:10.1007/s10585-006-9050-x
47. Murakami Y, Mitsudomi T, Yatabe Y (2012) A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol 2:24. doi:10.3389/fonc.2012.00024
48. Fischer AH, Schwartz MR, Moriarty AT, Wilbur DC, Souers R, Fatheree L, Booth CN, Clayton AC, Kurtyz DF, Padmanabhan V, Crothers BA (2014) Immunohistochemistry practices of cytopathology laboratories: a survey of participants in the College of American Pathologists Nongynecologic Cytopathology Education Program. Arch Pathol Lab Med 138(9):1167–1172. doi:10.5858/arpa.2013-0259-CP
49. Kirbis IS, Maxwell P, Flezar MS, Miller K, Ibrahim M (2011) External quality control for immunocytochemistry on cytology samples: a review of UK NEQAS ICC (cytology module) results. Cytopathology 22(4):230–237. doi:10.1111/j.1365-2303.2011.00867.x
50. Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL (2015) Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 28(4):468–479. doi:10.1038/modpathol.2014.107
51. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP (2014) Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20(12):1479–1484. doi:10.1038/nm.3729
52. Ribeiro-Silva A, Zhang H, Jeffrey SS (2007) RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol 8:118. doi:10.1186/1471-2199-8-118
53. Gruber K, Horn H, Kalla J, Fritz P, Rosenwald A, Kohlhaufl M, Friedel G, Schwab M, Ott G, Kalla C (2014) Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J Thorac Oncol 9(3):307–315. doi:10.1097/JTO.0000000000000068
54. Moskalev EA, Frohnauer J, Merkelbach-Bruse S, Schildhaus HU, Dimmler A, Schubert T, Boltze C, Konig H, Fuchs F, Sirbu H, Rieker RJ, Agaimy A, Hartmann A, Haller F (2014) Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. Lung Cancer 84(3):215–221. doi:10.1016/j.lungcan.2014.03.002
55. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M (2014) A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn 16(2):229–243. doi:10.1016/j.jmoldx.2013.11.007
56. Thermo Fisher Scientific. Oncomine™ Solid Tumour Fusion Transcript Kit Product Information. Available at https://www.thermofisher.com/uk/en/home/clinical/molecular-diagnostics/oncology-diagnostics.html
57. Swanton C, Govindan R (2016) Clinical implications of genomic discoveries in lung cancer. N Engl J Med 374(19):1864–1873. doi:10.1056/NEJMra1504688
58. Cha YJ, Lee JS, Kim HR, Lim SM, Cho BC, Lee CY, Shim HS (2014) Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 9(7):e103333. doi:10.1371/journal.pone.0103333
59. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M, College of American Pathologists International Association for the Study of Lung C, Association for Molecular P (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15(4):415–453. doi:10.1016/j.jmoldx.2013.03.001
60. Felip E, Concha Á, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F (2015) Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 17(2):103–112. doi:10.1007/s12094-014-1248-9
61. Zhang N, Yang JJ, Zhang XC, Xie Z, Wang BC, Tu HY, Jiang BY, Wu YL (2014) Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report. Oncol Lett 8(6):2624–2626. doi:10.3892/ol.2014.2571
62. Jurmeister P, Lenze D, Berg E, Mende S, Schaper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M (2015) Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer 87(2):122–129. doi:10.1016/j.lungcan.2014.11.018
63. Bussolati G, Annaratone L, Medico E, D'Armento G, Sapino A (2011) Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One 6(6):e21043. doi:10.1371/journal.pone.0021043
64. Bussolati G, Annaratone L, Maletta F (2015) The pre-analytical phase in surgical pathology. Recent Results Cancer Res 199:1–13. doi:10.1007/978-3-319-13957-9_1
65. Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, Kerr K, Schuuring E, Thunnissen E, Dequeker EM (2014) The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One 9(11):e112159. doi:10.1371/journal.pone.0112159
66. Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T (2013) Mouse model for ROS1-rearranged lung cancer. PLoS One 8(2):e56010. doi:10.1371/journal.pone.0056010
67. Cai W, Li X, Su C, Fan L, Zheng L, Fei K, Zhou C, Manegold C, Schmid-Bindert G (2013) ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol 24(7):1822–1827. doi:10.1093/annonc/mdt071
68. Cheng H, Ye L, Xue L (2014) Detection of ROS1 gene rearrangement by FISH and analysis of its clinical features in non-small cell lung cancer patients. Zhonghua Zhong Liu Za Zhi 36(10):751–754
69. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18(17):4570–4579. doi:10.1158/1078-0432.CCR-12-0550
70. Fu S, Liang Y, Lin YB, Wang F, Huang MY, Zhang ZC, Wang J, Cen WJ, Shao JY (2015) The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS One 10(4):e0124354. doi:10.1371/journal.pone.0124354
71. Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH (2013) Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 8(11):1445–1450. doi:10.1097/JTO.0b013e3182a4dd6e
72. Jin Y, Sun PL, Kim H, Park E, Shim HS, Jheon S, Kim K, Lee CT, Chung JH (2015) ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Arch 466(1):45–52. doi:10.1007/s00428-014-1679-2
73. Karlsson A, Brunnstrom H, Lindquist KE, Jirstrom K, Jonsson M, Rosengren F, Reutersward C, Cirenajwis H, Borg A, Jonsson P, Planck M, Jonsson G, Staaf J (2015) Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget 6(26):22028–22037. doi:10.18632/oncotarget.4314
74. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24(9):2364–2370. doi:10.1093/annonc/mdt220
75. Kirita K, Izumo T, Matsumoto Y, Hiraishi Y, Tsuchida T (2016) Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer. Lung. doi:10.1007/s00408-016-9864-5
76. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6(11):e28204. doi:10.1371/journal.pone.0028204
77. Matsuura S, Shinmura K, Kamo T, Igarashi H, Maruyama K, Tajima M, Ogawa H, Tanahashi M, Niwa H, Funai K, Kohno T, Suda T, Sugimura H (2013) CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncol Rep 30(4):1675–1680. doi:10.3892/or.2013.2630
78. Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K (2014) Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget 5(8):2293–2304. doi:10.18632/oncotarget.1906
79. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Kruger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Buttner R, Wolf J (2015) ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 6(12):10577–10585. doi:10.18632/oncotarget.3387
80. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M (2012) Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18(24):6599–6608. doi:10.1158/1078-0432.CCR-12-0838
81. Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, Li B, Shen L, Sun Y, Chen H (2015) Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 6(33):34300–34308. doi:10.18632/oncotarget.5549
82. Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, Schirmacher P, Penzel R, Weichert W (2014) ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 65(2):187–194. doi:10.1111/his.12379
83. Zhang Q, Sun T, Kang P, Qian K, Deng B, Zhou J, Wang R, Jiang B, Li K, Liu F, Wu S, Tan Q (2016) Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance. Cancer Chemother Pharmacol 77(3):583–593. doi:10.1007/s00280-016-2969-y
84. Zhao C, Li X, Li J, Zhang Y, Ren S, Chen X, Zhou C (2014) Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. Transl Oncol 7(3):363–367. doi:10.1016/j.tranon.2014.04.013
85. Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y (2015) Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation. Zhonghua Bing Li Xue Za Zhi 44(9):639–643
86. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA (2015) Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res 21(16):3631–3639. doi:10.1158/1078-0432.CCR-14-2683
87. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2(20):20ra14. doi:10.1126/scitranslmed.3000702